<?xml version='1.0' encoding='utf-8'?>
<document id="20706860"><sentence text="Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma."><entity charOffset="38-47" id="DDI-PubMed.20706860.s1.e0" text="sorafenib" /><entity charOffset="56-63" id="DDI-PubMed.20706860.s1.e1" text="calcium" /><entity charOffset="80-90" id="DDI-PubMed.20706860.s1.e2" text="felodipine" /><pair ddi="false" e1="DDI-PubMed.20706860.s1.e0" e2="DDI-PubMed.20706860.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20706860.s1.e0" e2="DDI-PubMed.20706860.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20706860.s1.e0" e2="DDI-PubMed.20706860.s1.e2" /><pair ddi="false" e1="DDI-PubMed.20706860.s1.e1" e2="DDI-PubMed.20706860.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20706860.s1.e1" e2="DDI-PubMed.20706860.s1.e2" /></sentence><sentence text="Sorafenib, an orally active multi-kinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC), is primarily metabolized both via cytochrome P450 3A4 isoform (CYP3A4) and UGT1A9"><entity charOffset="0-9" id="DDI-PubMed.20706860.s2.e0" text="Sorafenib" /></sentence><sentence text=" Due to the contribution of these two biotransformation pathways, sorafenib is considered to be less susceptible than other agents to CYP3A4 drug-drug interactions"><entity charOffset="66-75" id="DDI-PubMed.20706860.s3.e0" text="sorafenib" /></sentence><sentence text=" This report discusses a clinically relevant pharmacokinetic CYP3A4 drug-drug interaction between sorafenib and felodipine in an 80-year-old Caucasian patient with HCC"><entity charOffset="98-107" id="DDI-PubMed.20706860.s4.e0" text="sorafenib" /><entity charOffset="112-122" id="DDI-PubMed.20706860.s4.e1" text="felodipine" /><pair ddi="false" e1="DDI-PubMed.20706860.s4.e0" e2="DDI-PubMed.20706860.s4.e0" /><pair ddi="false" e1="DDI-PubMed.20706860.s4.e0" e2="DDI-PubMed.20706860.s4.e1" /></sentence><sentence text=" On day 15, after the introduction of sorafenib (400 mg bid), sorafenib plasma concentration was at 3"><entity charOffset="38-47" id="DDI-PubMed.20706860.s5.e0" text="sorafenib" /><entity charOffset="62-71" id="DDI-PubMed.20706860.s5.e1" text="sorafenib" /><pair ddi="false" e1="DDI-PubMed.20706860.s5.e0" e2="DDI-PubMed.20706860.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20706860.s5.e0" e2="DDI-PubMed.20706860.s5.e1" /></sentence><sentence text="6 mg/L" /><sentence text=" Felodipine (5 mg bid), an anti-hypertensive agent that is exclusively CYP3A4 substrate, was then introduced due to grade 2 sorafenib-related hypertension"><entity charOffset="1-11" id="DDI-PubMed.20706860.s7.e0" text="Felodipine" /><entity charOffset="124-133" id="DDI-PubMed.20706860.s7.e1" text="sorafenib" /><pair ddi="false" e1="DDI-PubMed.20706860.s7.e0" e2="DDI-PubMed.20706860.s7.e0" /><pair ddi="false" e1="DDI-PubMed.20706860.s7.e0" e2="DDI-PubMed.20706860.s7.e1" /></sentence><sentence text=" On day 30, hypertension was well controlled" /><sentence text=" However, sorafenib plasma concentration was 3-fold greater (11"><entity charOffset="10-19" id="DDI-PubMed.20706860.s9.e0" text="sorafenib" /></sentence><sentence text="4 mg/L) and the patient experienced grade-3 anorexia" /><sentence text=" Since neither diarrhea nor cutaneous side effects were noticed at this time, sorafenib treatment was continued at the same daily dosage"><entity charOffset="78-87" id="DDI-PubMed.20706860.s11.e0" text="sorafenib" /></sentence><sentence text=" On day 45, sorafenib plasma concentration was stable (10"><entity charOffset="12-21" id="DDI-PubMed.20706860.s12.e0" text="sorafenib" /></sentence><sentence text="8 mg/L) before declining on days 60 and 75 (7" /><sentence text="0 mg/L and 7" /><sentence text="4 mg/L, respectively), which was probably related to an occurrence of grade-2 diarrhea" /><sentence text=" This observation suggests a pharmacokinetic interaction involving CYP3A4 inhibition by felodipine"><entity charOffset="88-98" id="DDI-PubMed.20706860.s16.e0" text="felodipine" /></sentence><sentence text=" According to the Drug Interaction Probability Scale, this interaction was possible" /><sentence text=" Since hypertension is a common toxicity of sorafenib, clinicians should be aware of this possible interaction"><entity charOffset="44-53" id="DDI-PubMed.20706860.s18.e0" text="sorafenib" /></sentence><sentence text=" The clinical relevance of pharmacokinetic interactions involving CYP3A4 inhibition in HCC patients receiving sorafenib is analyzed in this case report"><entity charOffset="110-119" id="DDI-PubMed.20706860.s19.e0" text="sorafenib" /></sentence><sentence text="" /></document>